Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting
March 11 2021 - 7:00AM
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company
leveraging its proprietary DNAbilize™ liposomal delivery and
antisense technology to develop a portfolio of targeted nucleic
acid cancer drugs, today announced an upcoming virtual poster
presentation at the 2021 American Association for Cancer
Research (AACR) Annual Meeting, taking place April 10-15 and May
17-21, 2021.
Dr. Maria Gagliardi, a Research Scientist at
Bio-Path Holdings, will discuss pre-clinical studies of BP1002
(liposomal Bcl-2 antisense) in combination with decitabine as a
potential treatment against venetoclax-resistant cells. Details for
the virtual poster presentation are as follows:
Date: April 10, 2021Presentation
Time: 8:30 am Eastern
TimeSession: Biological Therapeutic
AgentsAbstract
Number: 939Title: The combination of
liposomal Bcl-2 antisense oligonucleotide (BP1002) with decitabine
is efficacious in venetoclax-resistant cells
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing
DNAbilize®, a novel technology that has yielded a pipeline of
RNAi nanoparticle drugs that can be administered with a simple
intravenous transfusion. Bio-Path’s lead product candidate,
prexigebersen (BP1001, targeting the Grb2 protein), is in a
Phase 2 study for the treatment of blood cancers and
prexigebersen-A, a drug product modification of prexigebersen, is
under consideration by the FDA to commence Phase 1 studies in solid
tumors. This is followed by BP1002, targeting the Bcl-2 protein,
where it is being evaluated in a Phase 1 study in advanced lymphoma
and chronic lymphocytic leukemia patients.
For more information, please visit the Company's
website at http://www.biopathholdings.com. Contact
Information:
Investors
Will O’ConnorStern Investor Relations,
Inc.212-362-1200will@sternir.com
Doug MorrisInvestor RelationsBio-Path Holdings,
Inc.832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Apr 2023 to Apr 2024